Event: Thursday, July 30, 2026
Results: by 6:30 a.m. ET | Conference call: 8:30 a.m. ET
Stock reference: CI closed at $297.15 on July 29, up roughly 6.5% year to date.
CI enters 2Q with a favorable setup operationally but a relatively clear bar: management explicitly framed 2Q adjusted EPS at approximately 25% of its full-year outlook. On the current at-least-$30.35 FY26 adjusted-EPS guide, that implies roughly $7.59 of 2Q adjusted EPS. The key question is therefore less whether CI can produce a solid headline number, and more whether it can reaffirm or raise its full-year outlook while demonstrating that:
The Q1 report gave CI meaningful cushion: adjusted EPS of $7.79 was up 16% year over year, Cigna Healthcare beat internal expectations, and FY26 guidance was lifted by $0.10 to at least $30.35. CI then reaffirmed that guide at its May investor meetings. That combination makes a full-year guide cut unlikely absent a material change in medical-cost trends or PBM economics—but it also raises the bar for an upside surprise.
| Metric | Management framework entering 2Q26 | Why it matters |
|---|---|---|
| Adjusted EPS | Approximately 25% of FY26 adjusted EPS outlook | Implies approximately $7.59, using the $30.35 annual guide |
| FY26 adjusted EPS | At least $30.35 | The principal headline and most important stock-moving item |
| Evernorth pretax adjusted income | At least $6.9B for FY26 | Specialty growth must offset PBS contract and investment headwinds |
| Cigna Healthcare pretax adjusted income | At least $4.525B for FY26 | Q1 strength led to a $25M increase in this outlook |
| Cigna Healthcare MCR | 83.7%–84.7% for FY26 | Management said 2Q should be slightly above the high end of the full-year range |
| Cigna Healthcare earnings cadence | First half slightly above 60% of FY26 segment earnings | Q2 should remain a substantial contributor despite a higher seasonal MCR |
Important framing: a Q2 MCR above 84.7% should not be viewed automatically as a miss. Management specifically guided to a second-quarter MCR modestly above the annual range due to normal seasonality, the post-Medicare-divestiture business mix, a greater mix of Bronze exchange members, and timing effects from Q1 care deferrals.
Cigna Healthcare posted a 79.8% MCR in Q1, materially below the 82.2% recorded a year earlier. Management attributed the better-than-expected result to disciplined pricing and execution, lower flu/respiratory volumes, weather-related deferral of care, and exchange-business mix.
Crucially, management said healthcare cost trends remain elevated but have not accelerated. That distinction matters: CI has priced for higher cost trends, so stable rather than worsening utilization supports the credibility of the FY26 guide.
The underlying Cigna Healthcare business is now more concentrated in commercial employer and international markets following the March 2025 sale of its Medicare businesses to HCSC. In Q1, adjusted revenue excluding divested businesses grew 8%, primarily through premium-rate increases intended to cover expected medical-cost inflation. Segment pretax adjusted income rose 18% to $1.514B.
Evernorth remains the most important long-term earnings engine, but its two major components are moving in opposite directions.
In Q1, Specialty & Care Services delivered:
Management characterized the segment as its fastest-growing platform and expects it to operate at the high end of its 8%–12% annual growth framework. Key drivers include the secular growth in specialty medicines, greater adoption of lower-cost biosimilars—including Humira and Stelara alternatives—and the expanded hospital/health-system capabilities from CarepathRx and Shields.
For 2Q: another quarter of strong Specialty & Care earnings would validate that CI is successfully repositioning toward higher-value pharmacy and care services. The quality of growth matters: volume growth, biosimilar conversion, mix, and margins should be watched more closely than reported revenue alone.
PBS was the weak point in Q1, with pretax adjusted income down 28% year over year to $394M. The decline reflected:
Management indicated that Signature investment spending is weighted toward the second half of 2026, meaning the quarter could show more visible pressure in PBS profitability even if the year remains on plan.
The strategic question is whether Signature can modernize CI’s PBM offering and protect its competitive position amid regulatory and employer demand for greater drug-price transparency. CI expects Signature to become its standard PBS model in 2028 and targets at least 50% of PBS members on the model by year-end 2028. For 2027, management has cited mid-90%-plus retention and early new-business wins, but investors will want more tangible evidence on adoption and economics.
For 2Q, listen for:
CI’s pharmacy thesis depends on its ability to help clients manage high-cost drug categories while maintaining value to patients.
Management said coverage for weight-management GLP-1s has remained broadly stable: approximately 50% of Evernorth clients and 20% of Cigna Healthcare clients, with differing employer-market exposures. More than 12 million people were enrolled in CI’s EnCircle program as of the Q1 call.
The key issue is not simply GLP-1 utilization; it is the balance between employer demand, affordability, clinical adherence, and potential savings from future oral formulations and lower net prices. Investors should look for signs that this category is either tracking within assumptions or becoming a greater source of client budget pressure.
This is a clearer positive. CI has promoted zero-out-of-pocket biosimilar options in categories including Humira and Stelara, and expects generic Revlimid availability to improve as supply constraints ease. Higher biosimilar conversion can reduce client costs while supporting Evernorth’s specialty margin and clinical value proposition.
This is the first quarterly report since Brian Evanko became CEO on July 1, 2026; former CEO David Cordani moved to Executive Chair.
The immediate implication should be continuity rather than a reset. Evanko’s stated priorities are:
The call will be important for establishing how aggressively Evanko intends to pursue these priorities and whether there is any incremental color on strategic alternatives for eviCore, which CI placed under review in Q1. A transaction is not required for the thesis, but monetization or a partnership could further sharpen CI’s focus on core platforms and improve capital flexibility.
CI ended Q1 with a 42.3% debt-to-capitalization ratio, down from 43.0% at year-end 2025. Management expects further improvement by year-end while balancing debt reduction, dividends, repurchases, and targeted bolt-on M&A.
Items to monitor:
CI is positioned as a commercial managed-care and health-services compounder, rather than a Medicare-heavy insurer. That distinction has been valuable in an uneven managed-care environment. The company’s most important near-term differentiators are its commercial insurance discipline, specialty-pharmacy growth, and the strategic evolution of Evernorth’s PBM offering.
For 2Q, the most constructive result would be a clean delivery against the roughly $7.59 adjusted-EPS cadence, a seasonal but well-controlled MCR increase, ongoing Specialty & Care momentum, and an unchanged-to-higher FY26 guide. The most important risk is not a single quarterly headline metric; it is whether commentary suggests that medical-cost or PBS pressures are becoming structurally worse than management’s current assumptions.